Loading
Solventum Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 11 Mar 2026.
Solventum Corp: what insiders have been doing
Solventum Corp, founded in 2024, is a Healthcare & Pharma company based in Eagan, United States. Its latest reported headcount is 20,000 employees (2025). Its directors and officers file their transactions with SEC (Form 4). Over the twelve months to 18 October 2026, 44 filings were filed, from 18 insiders.
Every open-market trade in the period is a purchase: 1 purchase worth €86k, from 1 insider, and not a single sale. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. The largest single trade was a purchase of €86k by Wendell Amy McBride, published on 11 March 2026. The buyers include 1 senior executive.
With 44 filings in twelve months, the company is more active than the median of 19 filings across the 5,814 companies we follow on the same exchange. Our records for Solventum Corp go back to 2024, with 1 purchase and 1 sale on the open market in total. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 8.32 bn USD and net income at 1.56 bn USD.
The clock since the last published purchase (11 March 2026) now reads 221 days. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade.
Elsewhere in the same sector, our signals recently picked up insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
75
Thresholds
n/a
Buy Volume
€86,375
1 ops. · all time
Sell Volume
€555M
1 ops. · all time
Who traded when
BuySaleAmy McBride Wendell1 buy
Co 3m1 sale
Since the insiders bought
- +32.9%Entry US$66.12 · Close 15 Oct 2026 US$87.86
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Solventum Corp Buy (bullish), based on 13 analysts. Average price target: US$94.69.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 3,263 of 24,161 companies
71.0
score / 100
Value66
Quality76
FCF yld-0.1%
Earn yld10%
EV/EBITDA7.8x
ROE34%
Gross mgn53%
Net mgn19%
Debt/EBITDA2.0x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$87.86
Analyst consensus
13 analystsBuy
US$71.00Target US$94.69(+8%)US$113.00
Income statement
RevenueUS$8.3B
Gross profitUS$4.5B53% margin
EBITDAUS$2.5B31% margin
Net incomeUS$1.6B17.3% margin
Valuation
PER (trailing)10.8x
PER (forward)12.1x
P/Book3.1x
Beta0.70
Balance sheet & cash
Market capUS$15B
Total debtUS$5B
Free Cash Flow-US$10M
Debt / Equity110%
Profitability & ownership
ROE34.0%
ROA2.7%
% insiders15.3%
% institutions75.9%
Last declaration on 3 September 2026
Declarations75 total
67,261 sharesCommon StockSEC:0001524349-26-000008:0
26,468 shares@ US$90.950.015% mcap100.0% of flowCommon StockSEC:0001524349-26-000008:1
4,488 shares0Common StockSEC:0001868881-26-000005:0
9,503 shares0Common StockSEC:0001768648-26-000005:0
4,422 shares0Common StockSEC:0002015813-26-000007:0
3,960 shares0Common StockSEC:0002015932-26-000005:0
34,315 shares0Common StockSEC:0001524349-26-000005:0
2,376 shares0Common StockSEC:0002016061-26-000005:0
3,960 shares0Common StockSEC:0001937481-26-000007:0
3,403 shares0Common StockSEC:0001587697-26-000004:0
3,403 shares0Common StockSEC:0001204663-26-000005:0
3,403 shares0Common StockSEC:0001161660-26-000005:0
3,403 shares0Common StockSEC:0001474632-26-000005:0
4,916 shares0Common StockSEC:0001110753-26-000004:0
3,403 shares0Common StockSEC:0001222831-26-000010:0
3,403 shares0Common StockSEC:0001958161-26-000007:0
3,403 shares0Common StockSEC:0001337906-26-000004:0
3,403 shares0Common StockSEC:0001808438-26-000005:0
3,403 shares0Common StockSEC:0001400568-26-000007:0
3,403 shares0Common StockSEC:0001755508-26-000006:0
5,199 shares0Common StockSEC:0002016061-26-000003:0
1,980 shares0Common StockSEC:0001808438-26-000003:0
1,980 shares0Common StockSEC:0001755508-26-000004:0
1,980 shares0Common StockSEC:0001474632-26-000003:0
1,980 shares0Common StockSEC:0001400568-26-000004:0
25 of 75 declarations
About Solventum Corp
Solventum Corp. (NYSE: SOLV) is a U.S.-listed healthcare company traded on the New York Stock Exchange in the United States, with headquarters in St. Paul, Minnesota, United States. The company became an independent public entity after the spin-off of 3M’s healthcare business was completed on April 1, 2024. Although Solventum is young as a standalone corporation, its operating heritage is much older, reflecting decades of development within 3M Health Care and a legacy of applied materials science, clinical know-how, and product innovation. ([solventum.com](https://www.solventum.com/en-ca/home/our-company/newsroom/press-releases/2024-04-01-solventum-begins-trading-on-the-new-york-stock-exchange/?utm_source=openai))
From a business perspective, Solventum operates as a diversified healthcare platform serving medical-surgical, dental, and health information technology customers. Its portfolio includes wound care and surgical solutions, infection prevention and other hospital consumables, dental restoratives and orthodontic materials, and digital health / clinical information systems that support healthcare workflows and data management. This mix gives the company exposure to recurring healthcare demand across providers, hospitals, clinics, and dental practices, while also tying it to regulated end markets where product quality and compliance are essential. ([solventum.com](https://www.solventum.com/en-us/home/our-company/leadership/?utm_source=openai))
Read moreShow less
Competitively, Solventum benefits from a strong installed base, trusted brands, and the technical depth inherited from 3M’s healthcare operations. Management positions the company as a global healthcare leader operating at the intersection of health, material science, and data science. That said, the competitive environment remains intense, with pressure from other medtech players, dental-product suppliers, and healthcare IT vendors, alongside ongoing regulatory, reimbursement, supply-chain, and product-liability risks typical of the sector. ([solventum.com](https://www.solventum.com/en-us/home/our-company/leadership/?utm_source=openai))
Geographically, Solventum is global, although investor communications continue to emphasize its U.S. base and international commercial reach. A key strategic development in 2025 was the announced sale of its Purification & Filtration business to Thermo Fisher Scientific for $4.1 billion. Management said the divestiture would sharpen the company’s focus on priority growth areas and support debt reduction. During 2025, Solventum also reported improving operating momentum, with positive organic growth, raised guidance, and a multi-year “Transform for the Future” initiative designed to improve execution and long-term value creation. ([investors.solventum.com](https://investors.solventum.com/news-events/press-releases/detail/99/solventum-announces-sale-of-its-purification-filtration-business-to-thermo-fisher-scientific-inc-for-4-1b?utm_source=openai))
For French-speaking investors, Solventum is best viewed as a post-spin healthcare restructuring story: a NYSE-listed U.S. company with a strong inherited franchise, broad healthcare exposure, and a more focused portfolio after recent divestiture activity. The key investment questions are execution of the transformation plan, margin discipline, balance-sheet repair, and the company’s ability to convert its technical heritage into sustained organic growth. ([investors.solventum.com](https://investors.solventum.com/news-events/press-releases/detail/143/solventum-reports-fourth-quarter-2025-financial-results-and-introduces-2026-full-year-guidance?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
